Feedback
Settings

Settings

Goto Application

121,194 results
Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 12,120
1.WO/2020/104533SINGLE-DOSE USE OF A COMPOSITION COMPRISING A PARTICULAR MIXTURE OF GRAPE EXTRACT AND BLUEBERRY EXTRACT
WO - 28.05.2020
Int.Class A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
 Appl.No PCT/EP2019/081945 Applicant ACTIV'INSIDE Inventor GAUDOUT, David
The invention concerns the use of a composition comprising at least a mixture of molecules obtained from Vitis vinifera and Vaccinium angustifolium, the mixture comprising: - at least 1% catechins and/or epicatechins, the percentage being given by weight relative to the total weight of the mixture, - at least 5 ppm (parts per million in the mixture) of ferulic acid, and - at least 200 ppm of resveratrol, as a single dose in humans or animals in order to improve or maintain cognitive functions.
2.WO/2020/106772EXOSOME LOADED THERAPEUTICS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, DIABETES MELLITUS TYPE 1 AND TYPE 2, ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, AND ALPHA 1 ANTITRYPSIN DEFICIENCY
WO - 28.05.2020
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
 Appl.No PCT/US2019/062293 Applicant EXOSOME THERAPEUTICS, INC. Inventor RODRIGUEZ-ARAUJO, Gerardo
A composition for delivering a cargo to the cytoplasm of a cell, wherein the cargo treats Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus Type 1 and Type 2, Atherosclerotic Cardiovascular Disease, and Alpha 1 Antitrypsin Deficiency. In another embodiment, the composition comprises: an exosome; cargo located inside the exosome, wherein the cargo comprises short interference RNA (siRNA) that depletes sodium-glucose linked transporter active sites. In another embodiment, the composition comprises: an exosome; cargo location inside the exosome, wherein the cargo corrects the missense SERPINA1 mutation from 'Z' to 'M'.
3.WO/2020/106982METHODS OF OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS
WO - 28.05.2020
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
 Appl.No PCT/US2019/062654 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor WELSH, James
Provided herein are methods of using BMP7 levels as a marker for the selection of patients, such as non-small cell lung cancer patients, who will clinically respond to combination therapy comprising a BMP7 inhibitor and an immune checkpoint therapy, such as an anti-PD1 therapy and/or an anti-CTLA-4 therapy. Also provided are methods of treating the selected patients with a combination of a BMP7 inhibitor and an immune checkpoint therapy.
4.WO/2020/103921PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO - 28.05.2020
Int.Class A61K 31/437
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
 Appl.No PCT/CN2019/120144 Applicant ASCENTAGE PHARMA (SUZHOU) CO., LTD. Inventor YANG, Dajun
Disclosed is a pharmaceutical composition comprising (i) a compound of formula (I) or a pharmaceutically acceptable salt thereof; (ii) a CDK inhibitor or a pharmaceutically acceptable salt thereof, for the prevention and/or treatment of a disease mediated by Bcl-2 and/or CDK activity.
5.WO/2020/104911COMBINATION OF CHEMOTHERAPY WITH RECOMBINANT S. ROLFSII LECTIN
WO - 28.05.2020
Int.Class A61K 31/337
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
337having four-membered rings, e.g. taxol
 Appl.No PCT/IB2019/059873 Applicant UNICHEM LABORATORIES LTD Inventor SATHE, Dhananjay
The present invention relates to the combination chemotherapy with recombinant lectin protein. The invention specifically relates to the cytotoxic effect of recombinant lectin protein having amino acid sequence of SEQ ID NO: 1 in combination with other therapeutic agents, wherein the other therapeutic agents are anti-cancer agents. The combinations are highly synergistic and efficacious against several cancers.
6.WO/2020/106051PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, COMPRISING BOTH STREPTONIGRIN AND ANTICANCER AGENT
WO - 28.05.2020
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
 Appl.No PCT/KR2019/015908 Applicant MD BIOLAB CO., LTD. Inventor KIM, Soo Youl
The present invention relates to a pharmaceutical composition or an anticancer adjuvant for use in prevention or treating cancer, the composition or adjuvant comprising both of: streptonigrin; and at least one additional anticancer agent selected from the group consisting of bortezomib, rapamycin, and gemcitabine. In addition, the present invention relates to a method for prevention or treatment of cancer, the method comprising a step of administering to a patient a pharmaceutical composition comprising both of: streptonigrin; and at least one additional anticancer agent selected from the group consisting of bortezomib, rapamycin, and gemcitabine. Therefore, the composition comprising all of streptonigrin and other anticancer agents according to the present invention has the excellent effect of inhibiting the growth of cancer cells, particularly, breast cancer cells and as such, can be effectively used in a cancer prevention or treatment composition or a cancer prevention or treatment method using same.
7.WO/2020/106050PHARMACEUTICAL COMPOSITION COMPRISING BOTH STREPTONIGRIN AND ANTI-CANCER AGENT FOR PREVENTING OR TREATING CANCER
WO - 28.05.2020
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
 Appl.No PCT/KR2019/015907 Applicant MD BIOLAB CO., LTD. Inventor KIM, Soo Youl
The present invention relates to a pharmaceutical composition or an adjuvant anti-cancer agent for preventing or treating cancer comprising both streptonigrin and and one or more anti-cancer agents selected from the group consisting of cisplatin, gemcitabine, and paclitaxel. Additionally, the present invention relates to a method for preventing or treating cancer comprising the step for administering, to a patient, the pharmaceutical composition comprising both streptonigrin and one or more anti-cancer agents selected from the group consisting of cisplatin, gemcitabine, and paclitaxel. Therefore, the composition according to the present invention comprising both streptonigrin and other anti-cancer agents is highly effective in inhibiting cancer cell growth, especially the growth of ovarian cancer cells, and thus can be effectively used in a composition or method using the composition for preventing or treating cancer.
8.WO/2020/104479METHODS AND COMPOSITIONS FOR TREATING CANCERS AND RESISTANT CANCERS WITH ANTI TRANSFERRIN RECEPTOR 1 ANTIBODIES
WO - 28.05.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/EP2019/081845 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor POUL, Marie-Alix
Inventors have used an antibody (H7) which works by a special mechanism upregulating TfR1 levels which is not observed by other anti-TfR1 antibodies which usually block Tfbinding and internalization via blocking the TfR1 on the cell surface or directing it for lysosomal degradation resulting in decreased TfR1 levels. Interestingly, inventors have demonstrated for the first time with a naked anti-TfR1 antibody a complete inhibition of cell viability at less than 10 μg/ml of the antibody on a solid colon cancer cell line HCT116 at a low IC50 of 0.78 μg/ml. Inventors have shown that in vivo, H7 decreased the tumor growth of the PDAC patient derived xenograft (PDX) model and improved the gemcitabine efficiency on the BxPC3 xenograft mice model. Accordingly, inventors have shown that H7 antibody has the characteristics and qualifications that allow it to be tried in clinical trials. It is fully human, highly efficient in blocking iron supply from transferrin, and induces ADCC.
9.WO/2020/106049PHARMACEUTICAL COMPOSITION COMPRISING BOTH STREPTONIGRIN AND ANTI-CANCER AGENT FOR PREVENTING OR TREATING CANCER
WO - 28.05.2020
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
 Appl.No PCT/KR2019/015906 Applicant MD BIOLAB CO., LTD. Inventor KIM, Soo Youl
The present invention relates to a pharmaceutical composition or an adjuvant anti-cancer agent comprising both streptonigrin and gemcitabine for preventing or treating cancer. Additionally, the present invention relates to a method for preventing or treating cancer comprising the step for administering the pharmaceutical composition comprising both streptonigrin and gemcitabine to a patient, Therefore, the composition according to the present invention comprising both streptonigrin and other anti-cancer agents is highly effective in inhibiting cancer cell growth, especially the growth of pancreatic cancer cells, and thus can be effectively used in a composition or method using the composition for preventing or treating cancer.
10.WO/2020/103878ER PROTEIN REGULATOR AND APPLICATION THEREOF
WO - 28.05.2020
Int.Class A61K 31/137
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
 Appl.No PCT/CN2019/119766 Applicant SHANGHAITECH UNIVERSITY Inventor YANG, Xiaobao
An ER protein regulator compound represented by formula (I) and an application thereof. LIN in the compound represented by formula (I) is a linking unit; ULM is a small-molecule ligand of VHL or CRBN protease having a ubiquitylation function; and group X is CH 2, O or NH, and group X is covalently linked to ULM by means of the linking group LIN. The series of compounds which is designed and synthesized has wide pharmacological activity, has the function of regulating ER protein and inhibiting the activity of tumors, and can be used for preventing and/or treating diseases and symptoms related with estrogen receptors, or related tumor treatment.
# -